Ribavirin
Active ingredient: Ribavirin
In short: Ribavirin capsules in combination with interferon alfa-2b (pegylated and nonpegylated) are indicated for the treatment of Chronic Hepatitis C (CHC) in patients 3 years of age and older with compensated liver disease . The following points should be considered when initiating ribavirin capsules combi
What is Ribavirin used for?
Ribavirin capsules in combination with interferon alfa-2b (pegylated and nonpegylated) are indicated for the treatment of Chronic Hepatitis C (CHC) in patients 3 years of age and older with compensated liver disease .
The following points should be considered when initiating ribavirin capsules combination therapy with PegIntron® or INTRON A®:
Combination therapy with ribavirin capsules/PegIntron is preferred over ribavirin capsules/INTRON A as this combination provides substantially better response rates .
Patients with the following characteristics are less likely to benefit from re-treatment after failing a course of therapy: previous nonresponse, previous pegylated interferon treatment, significant bridging fibrosis or cirrhosis, and genotype 1 infection .
No safety and efficacy data are available for treatment duration lasting longer than one year.
âš Boxed warning (FDA's strongest warning)
Significant teratogenic and embryocidal effects have been demonstrated in all animal species exposed to ribavirin. In addition, ribavirin has a multiple-dose half-life of 12 days and may persist in non-plasma compartments for as long as 6 months. Therefore, ribavirin
therapy is contraindicated in women who are pregnant and in the male partners of women who are pregnant. Avoid pregnancy and use effective contraception during therapy and for 9 months after completion of treatment in female patients and for 6 months in female partners of male patients who are taking ribavirin therapy.
[see Contraindications (4), Warnings and Precautions (5.1), Use in Specific Populations (8.1, 8.3), and Nonclinical Toxicology (13.1)].
Hemolytic anemia has been reported with ribavirin therapy. The anemia associated with ribavirin therapy may result in worsening of cardiac disease that has led to fatal and nonfatal myocardial infarctions. Patients with a history of significant or unstable cardiac disease should not be treated with ribavirin [see Dosage and Administration (2.5), Warnings and Precautions (5.2), and
Adverse Reactions (6.1)].
Ribavirin monotherapy is not effective for the treatment of chronic hepatitis C virus infection and should not be used alone for this indication .
Ribavirin dosage
Do not open, crush or break ribavirin capsules. Ribavirin capsules should be taken with food .
Adult Patients
The recommended dose of ribavirin capsules when used in combination with PegIntron is 800 mg to 1,400 mg based on patient body weight in two divided doses . Refer to PegIntron labeling for PegIntron dosing information.
Duration of Treatment – Interferon Alpha-naïve Patients
The treatment duration for patients with genotype 1 is 48 weeks. Discontinuation of therapy should be considered in patients who do not achieve at least a 2 log10 drop or loss of hepatitis C virus (HCV)-RNA at 12 weeks, or if HCV-RNA remains detectable after 24 weeks of therapy. Patients with genotype 2 and 3 should be treated for 24 weeks.
Duration of Treatment – Re-treatment with PegIntron/Ribavirin capsules of Prior Treatment Failures
The treatment duration for patients who previously failed therapy is 48 weeks, regardless of HCV genotype. Re-treated patients who fail to achieve undetectable HCV-RNA at Week 12 of therapy, or whose HCV-RNA remains detectable after 24 weeks of therapy, are highly unlikely to achieve SVR and discontinuation of therapy should be considered .
Body Weight (kg) | Ribavirin capsules Daily Dose | Ribavirin Number of Capsules
Less than 66 | 800 mg/day | 2 x 200 mg capsules AM2 x 200 mg capsules PM
66 to 80 | 1,000 mg/day | 2 x 200 mg capsules AM3 x 200 mg capsules PM
81 to 105 | 1,200 mg/day | 3 x 200 mg capsules AM3 x 200 mg capsules PM
Greater than 105 | 1,400 mg/day | 3 x 200 mg capsules AM4 x 200 mg capsules PM
Pediatric Patients
Dosing of ribavirin in pediatric patients is determined by body weight. The recommended dose of ribavirin when used in combination with PegIntron in pediatric patients ages 3 to 17 years is 15 mg/kg/day in two divided doses . Refer to PegIntron labeling for PegIntron dosing information. The treatment duration for patients with genotype 1 is 48 weeks. Patients with genotype 2 and 3 should be treated for 24 weeks.
* Ribavirin Oral Solution may be used in any patient regardless of body weight.
Body Weight (kg) | Ribavirin Daily Dose | Ribavirin Number of Capsules
Less than 47 | 15 mg/kg/day | Use Ribavirin Oral Solution*
47 to 59 | 800 mg/day | 2 x 200 mg capsules AM2 x 200 mg capsules PM
60 to 73 | 1,000 mg/day | 2 x 200 mg capsules AM3 x 200 mg capsules PM
Greater than 73 | 1,200 mg/day | 3 x 200 mg capsules AM3 x 200 mg capsules PM
Adults
Duration of Treatment – Interferon Alpha-naïve Patients
The recommended dose of ribavirin capsules when used in combination with INTRON A depends on the patient’s body weight . Refer to Intron A labeling for interferon dosing information. The recommended duration of treatment for patients previously untreated with interferon is 24 to 48 weeks. …
How to take Ribavirin — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Anemia
The most common adverse experience occurring with ribavirin capsules is anemia, which may be severe . Advise patients that laboratory evaluations are required prior to starting therapy and periodically thereafter . Advise patients to be well hydrated, especially during the initial stages of treatment.
Embryo-Fetal Toxicity
Inform females of reproductive potential and pregnant women that ribavirin capsules may cause birth defects, miscarriage, and stillbirth. Advise females of reproductive potential that they must have a pregnancy test prior to initiating treatment and periodically during therapy. Advise female patients of reproductive potential to use effective contraception during treatment with ribavirin and for 9 months post therapy and male patients with female partners of reproductive potential to use effective contraception during treatment with ribavirin and for 6 months post therapy. Advise patients to notify the physician immediately in the event of a pregnancy [see Contraindications (4), Warnings and Precautions (5.1), and Use in Specific Populations (8.1, 8.3)]. …
Warnings & precautions
Do not take this medicine if: Ribavirin capsules combination therapy is contraindicated in:
pregnancy. Ribavirin capsules may cause fetal harm when administered to a pregnant woman. Ribavirin capsules are contraindicated in women who are pregnant or planning to become pregnant. If a patient becomes pregnant while taking ribavirin capsules, the patient should be apprised of the potential hazard to the fetus .
men whose female partners are pregnant
patients with known hypersensitivity reactions such as Stevens-Johnson syndrome, toxic, epidermal necrolysis, and erythema multiforme to ribavirin or any component of the product
patients with autoimmune hepatitis
patients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia)
patients with creatinine clearance less than 50 mL/min
when coadministered with didanosine because exposure to the active metabolite of didanosine (dideoxyadenosine 5’-triphosphate) is increased. Fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis, has been reported in patients receiving didanosine in combination with ribavirin .
Ribavirin capsules may cause birth defects, miscarriage or stillbirth. Ribavirin therapy should not be started until a report of a negative pregnancy test has been obtained immediately prior to planned initiation of therapy. Female patients should use effective contraception and have periodic monitoring with pregnancy tests during treatment and during the 9-month period after treatment has been stopped. Male patients and their female partners should use effective contraception during treatment and during the 6-month period after treatment has been stopped. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. …
Ribavirin side effects
The following serious adverse drug reactions are discussed in other sections of the labeling:
Embryo-Fetal Toxicity
Anemia
Pancreatitis
Pulmonary Disorders
Ophthalmic Disorders
Dental and Periodontal Disorders
Impact on Growth in Pediatric Patients
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Clinical trials with ribavirin in combination with PegIntron or INTRON A have been conducted in over 7,800 subjects from 3 to 76 years of age.
The primary toxicity of ribavirin is hemolytic anemia. Reductions in hemoglobin levels occurred within the first 1 to 2 weeks of oral therapy. Cardiac and pulmonary reactions associated with anemia occurred in approximately 10% of patients .
Greater than 96% of all subjects in clinical trials experienced one or more adverse reactions. The most commonly reported adverse reactions in adult subjects receiving PegIntron or INTRON A in combination with ribavirin were injection site inflammation/reaction, fatigue/asthenia, headache, rigors, fevers, nausea, myalgia and anxiety/emotional lability/irritability. …
Drug interactions
Exposure to didanosine or its active metabolite (dideoxyadenosine 5’-triphosphate) is increased when didanosine is coadministered with ribavirin, which could cause or worsen clinical toxicities; therefore, coadministration of ribavirin capsules and didanosine is contraindicated . Reports of fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in clinical trials.
Hepatic decompensation (some fatal) has occurred in cirrhotic HIV/HCV co-infected patients receiving combination antiretroviral therapy for HIV and interferon alpha and ribavirin. Patients receiving interferon with ribavirin and nucleoside reverse transcriptase inhibitors (NRTIs) should be closely monitored for treatment-associated toxicities, especially hepatic decompensation and anemia. Discontinuation of NRTIs should be considered as medically appropriate . Dose reduction or discontinuation of interferon, ribavirin, or both should also be considered if worsening clinical toxicities are observed, including hepatic decompensation (e.g., Child-Pugh greater than 6).
Ribavirin may antagonize the cell culture antiviral activity of stavudine and zidovudine against HIV. …
About this medicine
Ribavirin, is a synthetic nucleoside analogue (purine analogue). The chemical name of ribavirin is 1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide and has the following structural formula .
Figure 1: Structural Formula
Ribavirin USP is a white, crystalline powder. It is freely soluble in water and slightly soluble in anhydrous alcohol. The molecular formula is C8H12N4O5 and the molecular weight is 244.21.
Ribavirin capsules USP consist of a white to off-white granular powder in a white, opaque, gelatin capsule. Each capsule contains 200 mg ribavirin and the inactive ingredients microcrystalline cellulose, lactose monohydrate, povidone-K 30, and magnesium stearate. The capsule shell consists of titanium dioxide, sodium lauryl sulfate, and gelatin. The capsule is printed with edible ink containing black iron oxide.
Meets USP dissolution test 2.
How it works: Ribavirin is an anti-HCV agent . Single- and multiple-dose pharmacokinetic properties in adults are summarized in Table 11. Ribavirin was rapidly and extensively absorbed following oral administration.
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 35f99f76-f2ef-4a81-91ff-285419664be3. Read the full official label on DailyMed.
Related medicines
Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin